title: Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: P
authors.initials: P
authors.lastname: Torka
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: T
authors.initials: T
authors.lastname: Hahn
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: J
authors.initials: J
authors.lastname: Bertolo
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ross
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: P
authors.initials: P
authors.lastname: Paplham
authors.affiliation: Department of Hematology-oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Jankowski
authors.affiliation: Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: G
authors.initials: G
authors.lastname: Deeb
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: G
authors.initials: G
authors.lastname: Chen
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
authors.forename: P
authors.initials: P
authors.lastname: McCarthy
mesh_terms: D064591:Allografts; D046528:Chimerism; D002999:Clone Cells; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008875:Middle Aged; D020125:Mutation, Missense; D019653:Myeloablative Agonists / Q000494:pharmacology / Q000627:therapeutic use; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000235:genetics / Q000628:therapy*; D012038:Regeneration; D012074:Remission Induction; D019233:Retreatment; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation; D013920:Thrombocythemia, Essential / Q000150:complications / Q000235:genetics
chemical_list: D019653:Myeloablative Agonists; C507924:JAK2 protein, human; D053614:Janus Kinase 2